Original Research Article
Year: 2020 | Month: December | Volume: 7 | Issue: 12 | Pages: 371-375
Observational Study to Evaluate Effectiveness of Adding Empagliflozin to Uncontrolled Type 2 Diabetes Patients Who Were Uncontrolled On Metformin Rather Than Up Titrating the Metformin Dose
Khwaja Ahtesham Ahmad
Department of Medicine, Jamia Tibbiya Deoband, Saharanpur (U.P.)
ABSTRACT
Aim: The main objective of this prospective observational study to evaluate effectiveness of adding empagliflozin to uncontrolled type 2 diabetes patients who were uncontrolled on metformin rather than up titrating the metformin dose.
Material & Method: This was a prospective observational study conducted among 90 patients who had qualified as per the inclusion and exclusion criteria. After inclusion patients were divided into two groups one group 10 mg Empagliflozin OD were added with 1000 mg metformin OD (N=45) and in other group metformin were up titrated to 2000 mg OD (N=45) as this is considered as maximum tolerable dose of metformin.
Result: There was a significant weight reduction in Empa + Met group which was as high as 1 kg over 24 weeks’ time frame. Despite on adequate anti-hypertensive management in both the group further statistically significant reduction in both SBP and DBP were observed in Empa+Met group (10.2±3.5 mmHg and 7.2±2.6, respectively) which was not with Met group. There were a further statistically significant reduction in total cholesterol, triglyceride and LDL Cholesterol despite the group were on optimal dosage of lipid lowering therapy.
Conclusion: Empagliflozin 10 mg is a potent glucose lowering agent and should be added to patients who were initially uncontrolled with metformin monotherapy rather than up titrating metformin dose. Empagliflozin offer better pleotropic benefits when added as second line therapy to metformin.
Keywords: Empagliflozin, uncontrolled type 2 diabetes patients, metformin
[PDF Full Text]